These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 17583228)

  • 61. Pharmacological treatment of obesity.
    Mancini MC; Halpern A
    Arq Bras Endocrinol Metabol; 2006 Apr; 50(2):377-89. PubMed ID: 16767304
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Rimonabant and progression of atherosclerosis in obese persons.
    Dora JM; Scheffel RS
    JAMA; 2008 Jul; 300(3):280; author reply 280-1. PubMed ID: 18632538
    [No Abstract]   [Full Text] [Related]  

  • 63. STRADIVARIUS: a brave trial aimed at clarifying benefits of rimonabant therapy.
    Cardiovasc J Afr; 2008; 19(3):158-9. PubMed ID: 18568179
    [No Abstract]   [Full Text] [Related]  

  • 64. Does a weight loss medicine make sense for obese type 2 diabetes? New information on endocannabinoid blockers.
    McCall AL
    Curr Diab Rep; 2007 Oct; 7(5):329-32. PubMed ID: 18173964
    [No Abstract]   [Full Text] [Related]  

  • 65. Rimonabant in obese patients with type 2 diabetes.
    Randall MD; Kendall DA; Bennett AJ; O'Sullivan SE
    Lancet; 2007 Feb; 369(9561):555. PubMed ID: 17307094
    [No Abstract]   [Full Text] [Related]  

  • 66. Pharmacotherapy to reduce visceral fat.
    Blackburn GL; Waltman BA
    Clin Cornerstone; 2005; 7(2-3):52-60. PubMed ID: 16473261
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [New therapeutic aspects for the control of risk factors in obesity].
    Formiguera X; Sierra A
    Med Clin (Barc); 2007 Apr; 128(13):508-14. PubMed ID: 17419915
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists?
    Di Marzo V
    Nat Clin Pract Cardiovasc Med; 2008 Oct; 5(10):610-2. PubMed ID: 18695695
    [No Abstract]   [Full Text] [Related]  

  • 69. Rimonabant: a cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors.
    Tonstad S
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):156-62. PubMed ID: 16487916
    [TBL] [Abstract][Full Text] [Related]  

  • 70. End of the line for cannabinoid receptor 1 as an anti-obesity target? An opinion.
    Bifulco M; Pisanti S
    Nat Rev Drug Discov; 2009 Jul; 8(7):594. PubMed ID: 19568284
    [No Abstract]   [Full Text] [Related]  

  • 71. CB(1) blockade-induced weight loss over 48 weeks decreases liver fat in proportion to weight loss in humans.
    Bergholm R; Sevastianova K; Santos A; Kotronen A; Urjansson M; Hakkarainen A; Lundbom J; Tiikkainen M; Rissanen A; Lundbom N; Yki-Järvinen H
    Int J Obes (Lond); 2013 May; 37(5):699-703. PubMed ID: 22828945
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Treatments for metabolic syndrome may expand.
    Thompson CA
    Am J Health Syst Pharm; 2006 May; 63(10):894-7. PubMed ID: 16675641
    [No Abstract]   [Full Text] [Related]  

  • 73. Current pharmacotherapeutic concepts for the treatment of obesity in adults.
    Idelevich E; Kirch W; Schindler C
    Ther Adv Cardiovasc Dis; 2009 Feb; 3(1):75-90. PubMed ID: 19144669
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Obesity and cardiovascular physiology: impact of some pharmacological agents.
    Chaput JP; Bérubé-Parent S; Tremblay A
    Curr Vasc Pharmacol; 2005 Apr; 3(2):185-93. PubMed ID: 15853638
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Anti-obesity effects of the combined administration of CB1 receptor antagonist rimonabant and melanin-concentrating hormone antagonist SNAP-94847 in diet-induced obese mice.
    Verty AN; Lockie SH; Stefanidis A; Oldfield BJ
    Int J Obes (Lond); 2013 Feb; 37(2):279-87. PubMed ID: 22473329
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors.
    Gelfand EV; Cannon CP
    Expert Opin Investig Drugs; 2006 Mar; 15(3):307-15. PubMed ID: 16503766
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results.
    Ruilope LM; Després JP; Scheen A; Pi-Sunyer X; Mancia G; Zanchetti A; Van Gaal L
    J Hypertens; 2008 Feb; 26(2):357-67. PubMed ID: 18192851
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Rimonabant for the treatment of obesity.
    Samat A; Tomlinson B; Taheri S; Thomas GN
    Recent Pat Cardiovasc Drug Discov; 2008 Nov; 3(3):187-93. PubMed ID: 18991793
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pharmacotherapy for obesity in menopausal women.
    Samat A; Rahim A; Barnett A
    Menopause Int; 2008 Jun; 14(2):57-62. PubMed ID: 18519266
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Molecule of the month. Rimonabant hydrochloride.
    Drug News Perspect; 2004; 17(6):403. PubMed ID: 15334190
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.